Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin

• DOI: 10.1097/mca.0b013e328352ffec
• Publication Date: 2012-05-22T08:23:28Z
• Authors: Atsushi Iwata; Shin-ichiro Miura; Tohru Tanaka; Amane Ike; Makoto Sugihara; Hiroaki Nishikawa; Akira Kawamura; Keijiro Saku
• Keywords: Intravascular Ultrasound; PTX3; Fibrous cap; Vulnerable plaque

Objective Pentraxin 3 (PTX3) is a novel candidate immunoinflammatory marker that has been reported to be associated with cardiometabolic risk factors and predict adverse outcomes in patients coronary artery disease. The purpose of this study was investigate the association between plasma levels PTX3 plaque vulnerability effect using statin Methods We determined associations among nonculprit lesions stenosis as assessed by integrated backscatter intravascular ultrasound (study 1). One hundred eighteen consecutive stable angina who underwent percutaneous intervention were enrolled. also enrolled 53 angina, they treated either (n=36) or without (n=17) atorvastatin (10 mg/day) 2). Results In 1, although there no all patients, level positively correlated percentage lipid volume negatively fibrous treatment. There high-sensitivity C-reactive protein volume. Moreover, 2, therapy for 6–8 months significantly decreased addition protein. Conclusion may useful biomarker predicting tissue characteristics ultrasound. Statin have beneficial regard reduction levels.